Mechanistic insights into the activation of oncogenic forms of EGF receptor
- 20 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Structural & Molecular Biology
- Vol. 18 (12), 1388-1393
- https://doi.org/10.1038/nsmb.2168
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancerNature Clinical Practice Oncology, 2008
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)Cancer Research, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline InhibitorJournal of Biological Chemistry, 2002
- Cell Signaling by Receptor Tyrosine KinasesCell, 2000